GemPharmatech (SH:688046)2024-10-30 12:14Financial Performance - The company's operating revenue for Q3 2024 was ¥169,335,234.50, representing a year-on-year increase of 6.70%[2] - The net profit attributable to shareholders for Q3 2024 was ¥21,876,660.96, a decrease of 45.51% compared to the same period last year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2024 was ¥16,973,264.94, down 47.17% year-on-year[2] - The basic earnings per share for Q3 2024 was ¥0.05, a decline of 50.00% compared to the same period last year[2] - Net profit for the first three quarters of 2024 was CNY 98,214,378.60, a decrease of 16.5% compared to CNY 117,714,006.94 in the same period of 2023[20] - The total comprehensive income attributable to the parent company for Q3 2024 was ¥98,015,392.45, down from ¥118,112,827.90 in Q3 2023, indicating a decline of about 16.9%[21] - Basic and diluted earnings per share for Q3 2024 were both ¥0.24, compared to ¥0.29 in Q3 2023, representing a decrease of approximately 17.2%[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,533,540,486.16, a decrease of 1.71% from the end of the previous year[4] - Total assets as of the end of the third quarter of 2024 were CNY 2,533,540,486.16, a slight decrease from CNY 2,577,589,878.58 at the end of 2023[17] - Total liabilities as of the end of the third quarter of 2024 were CNY 410,226,296.03, down from CNY 452,933,434.26 in the previous year[17] - The company's cash and cash equivalents as of September 30, 2024, amount to approximately ¥490.78 million, a decrease from ¥560.17 million at the end of 2023[15] - The company's cash and cash equivalents decreased to CNY 341,384,959.63 from CNY 366,409,071.83 year-over-year[17] Cash Flow - The net cash flow from operating activities for the year-to-date was -¥15,900,959.72, reflecting a significant decrease of 142.80%[4] - Cash inflow from operating activities for the first three quarters of 2024 was ¥420,477,343.76, slightly up from ¥411,249,887.13 in the same period of 2023[22] - The net cash flow from operating activities for the first three quarters of 2024 was -¥15,900,959.72, a significant decline from ¥37,151,483.21 in the previous year[22] - The cash and cash equivalents at the end of Q3 2024 were ¥490,670,777.90, down from ¥661,682,486.12 at the end of Q3 2023, a decrease of approximately 26%[23] - The company reported a total cash outflow from operating activities of ¥436,378,303.47 for the first three quarters of 2024, compared to ¥374,098,403.92 in the same period of 2023, indicating an increase of about 16.7%[22] Research and Development - Research and development expenses for Q3 2024 amounted to ¥25,282,819.22, accounting for 14.93% of operating revenue, a decrease of 0.73 percentage points year-on-year[4] - Research and development expenses for the first three quarters of 2024 amounted to CNY 62,993,920.42, down 16.3% from CNY 75,305,788.45 in 2023[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 6,479[9] - The largest shareholder, Nanjing Laoyan Venture Capital Partnership, holds 201,817,185 shares, representing 49.22% of the total shares[9] - The top ten shareholders collectively hold a significant portion of the company's shares, with the top three alone accounting for over 57%[9] - There are no significant changes in the participation of major shareholders in margin trading or securities lending compared to the previous period[13] Market and Expansion - The company is currently in an expansion phase, which has led to increased costs and higher sales expenses as it intensifies efforts in overseas market development[7] - The company plans to continue focusing on market expansion and new product development in the upcoming quarters[20] Inventory and Receivables - Accounts receivable increased to approximately ¥376.00 million from ¥269.39 million year-over-year[15] - The company reported a significant increase in inventory, rising to approximately ¥57.94 million from ¥47.09 million[15] - The long-term equity investment increased to approximately ¥82.34 million from ¥69.20 million[15]